V-Ensure Pharma Technologies

About V-Ensure Pharma Technologies

Founded in 2010 by Sathyanarayana Vemula and Mousumi Satyanarayana Vemula, V-Ensure Pharma Technologies Private Limited operates as a specialty pharmaceutical company from its headquarters in Navi Mumbai, India. The firm concentrates on the development of complex generic formulations for regulated markets, establishing itself as a contract drug manufacturing organization. A significant milestone was achieved in February 2022, when the company secured $17.4 million in a funding round led by Investcorp, with participation from Tanas Capital.

V-Ensure's business model is centered on providing integrated services that span the pharmaceutical development lifecycle. The company functions as a contract research, development, and manufacturing organization (CDMO/CRO), specializing in creating patent non-infringing formulations. This involves developing pharmaceutical dossiers for regulated markets across a variety of dosage forms, including injectables, solid oral medications, and liquid oral solutions. The company's revenue is generated through these contract services, with reported revenues of ₹70.94 crore for the fiscal year 2023-24, a notable increase from the previous year.

The company's core services include formulation research and development, active pharmaceutical ingredient (API) R&D, analytical services, and cGMP manufacturing. V-Ensure has developed a diverse portfolio of drug products, including complex generics and specialty products like Bempedoic acid tablets and Acetaminophen IV solutions. Its facilities are equipped for a wide range of scientific formulation development and analytical testing, including a USFDA-approved analytical lab and an oral solids manufacturing facility designed to meet USFDA and EMA standards. The firm's expertise lies in navigating the complexities of patent landscapes and regulatory requirements, particularly for Para IV filings, which challenge existing patents.